-
1 Comment
Dimerix Limited is currently in a long term downtrend where the price is trading 13.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Dimerix Limited's total revenue sank by 33.7% to $1K since the same quarter in the previous year.
Its net income has dropped by 31.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.4% to $-924K since the same quarter in the previous year.
Based on the above factors, Dimerix Limited gets an overall score of 2/5.
ISIN | AU000000DXB7 |
---|---|
Sector | Healthcare |
Industry | Biotechnology |
Exchange | AU |
CurrencyCode | AUD |
Market Cap | 331M |
---|---|
Beta | 0.53 |
PE Ratio | None |
Target Price | 0.84 |
Dividend Yield | None |
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for DXB.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025